Login to Your Account



To the ‘Imaxio’: Vaccine Technology Seeks Immune Boost

By Marie Powers
Staff Writer

Thursday, September 12, 2013
After a decade of work, French vaccine developer Imaxio SA achieved a significant milestone when IMX313, its pro-immunogenic technology, was administered for the first time in humans in a Phase I tuberculosis (TB) vaccine trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription